ContextVision – Arto Järvinen appointed as the new CTO

ContextVision, Home, Investor News, News 2019-11-29
ContextVision is pleased to announce that Arto Järvinen has been promoted to the company’s CTO position. Järvinen has been Director of R&D since 2011 and has been instrumental in leading the company’s operational R&D work. Järvinen has succeeded the former CTO and co-founder Martin Hedlund. Hedlund retired earlier this year but will resume in his board position for the company.
Read More

ContextVision announces first digital pathology patent granted for its unique and objective data-generation method

ContextVision, Digital Pathology, Home, Investor News, News 2019-11-21
Master Annotation method has received patent protection in the U.S. The U.S. Patent and Trademark Office (USPTO) has granted a patent to ContextVision for this invention, titled “method and system for detecting pathological anomalies in a digital pathology image and method for annotating a tissue slide”.
Read More

ContextVision unveils latest innovation in advanced medical imaging

ContextVision, Home, Investor News, News 2019-11-18
ContextVision unveils latest innovation in advanced medical imaging At this year’s RSNA, ContextVision demonstrates RiventTM, taking image enhancement for ultrasound to a whole new level STOCKHOLM – Nov. 18, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, provides cutting-edge technology to support clinicians to accurately interpret medical images, […]
Read More

ContextVision – Strong Q3 with solid sales, good inflow of new customers and first product in digital pathology enters beta-testing phase

ContextVision, Financial reports, Home, Investor News, News 2019-10-24
STOCKHOLM – October 24, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, has seen a strong third quarter in 2019 as new customers have been added and the first product in digital pathology has entered the beta-testing phase. Q3 sales reached 23 MSEK and total sales are growing […]
Read More

ContextVision – Second quarter saw commercial release of first AI-based product, Altumira™, Digital Pathology on track and record sales

Financial reports, Home, Investor News, News 2019-08-15
STOCKHOLM – August 15, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, continued to advance its artificial intelligence portfolio in the second quarter 2019. The company’s AI-based product Altumira™ for X-ray is now commercially available and INIFY Prostate for digital pathology will soon move to beta testing in […]
Read More

ContextVision’s Deep Learning experts will hold an oral presentation at the Medical Imaging & Deep Learning conference in London July 8–10

Digital Pathology, Home, News 2019-06-12
This paper presents an interesting and novel idea of a deep learning (DL) framework to segment potentially cancerous areas in prostate biopsies using semi-automatically generated data. The application of this paper is quite innovative and the proposed method seems to be a direct assistance to the clinical routine.
Read More

ContextVision sees strong sales, continues focus on launch of AI-based digital pathology

Financial reports, Home, Investor News, News 2019-04-25
ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, reported strong sales in Q1, reaching 21.1 MSEK, 9% higher than the first quarter last year. The company reports positive feedback from user tests within digital pathology and continues to proceed with product development for this fast-growing market.
Read More

ContextVision signs agreement for research based on unique big data cohorts

Digital Pathology, Investor News, News, OEM 2019-03-28
ContextVision will have exclusive rights to the scanning cohort and access to anonymized associated clinical data - with cleared and structured histopathological descriptions, diagnosis and outcome data - for the defined patient cohorts and all commercial rights from output based on the data.The agreement gives ContextVision an opportunity to create AI-based decision support tools that will help doctors make more accurate treatment decisions. Today, many cancer patients suffer from life impairing side effects from treatments they did not need while other patients do not get treatment which is necessary.
Read More